Boehringer Ingelheim Taps ArisGlobal’s NavaX to Supercharge Pharmacovigilance with GenAI
In the high-stakes world of drug safety, speed and accuracy aren’t just nice to have—they’re life-critical. That’s why Boehringer Ingelheim, one of the largest pharma players globally, is betting big on AI to overhaul its pharmacovigilance operations. The company just rolled out LifeSphere® NavaX™, ArisGlobal’s GenAI-powered automation platform, to streamline how it processes individual case safety reports (ICSRs)—a fundamental, yet historically labor-intensive, part of drug safety.
